Desensitization in Kidney Transplantation

Completed · Phase 4

Conditions studied: HLA Sensitization

In brief

To determine if deletional strategies will provide effective desensitization.

Key facts

Study ID

NCT00908583

Run by

University of Cincinnati

People needed

44

Starts

2009-05-01

Expected to finish

2012-11-01

Last updated by the study team

2016-04-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 65
• Voluntary written informed consent
• Patient on deceased donor wait list with a current or peak cytotoxic or calculated panel reactive antibody (PRA) > 20%

You may not qualify if…

• Myocardial infarction within 6 months
• Patient received investigational drug within 14 days prior to initiation of study treatment
• Serious medical or psychological illness
• Diagnosed with malignancy within three years, except complete research of basal cell carcinoma or squamous cell carcinoma of skin, an insitu malignancy or low risk prostate cancer after curative therapy
• Absolute neutrophil count (ANC) < 1000
• Receipt of live vaccine within 4 weeks of study entry
• Female subject that is breast feeding

Where it is running

• The Christ Hospital — Cincinnati, Ohio, United States
• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.